Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Benefits Of Grapefruit

AMA Welcomes NHHRC Final Report, Australia
The AMA has congratulated the National Health and Hospitals Reform Commission on its final report launched in Canberra by Prime Minister Kevin Rudd.
generic viagra online
New Gene For Autism Gives Hope For Future
Scientists have discovered that abnormalities in a gene important for learning and memory are a cause of autism. The University of Aberdeen finding could hold the key to the future development of new treatments for autism - a brain development disorder which affects how a person communicates and relates to others. In a study published today in the Journal of Medical Genetics the researchers explain how their investigations into the gene EIF4E began with the study of one child with severe autism.
News of the day
Statement By HANYS' President Daniel Sisto Regarding The State Department Of Health Hospital-Acquired Infection Report
"Patients, policymakers, and practitioners all agree that reliable, accurate, and consistent quality measures are essential elements in improving health care services. This report is a clear indication that the efforts hospitals continue to make to prevent and control infections are having a positive impact on patient care. Hospitals are actively developing and sharing infection control techniques and best practices, and have engrained in their organizations a zero tolerance policy for preventable patient harm.
Oncology

Johnson & Johnson's Research Reflecting New Washington Policies

Health care supplier Johnson & Johnson will focus on new treatments and improved tests for cancer and other diseases for which company perceives unmet needs, like diabetes, hepatitis C, and HIV, as well as using new, Washington-supported research techniques to gauge their effectiveness, researchers and executives said at a briefing with analysts, BusinessWeek reports. Even as several major products have been waiting for Food and Drug Administration"s approval, analysts say the company has been making strides in its own clinical trials, according to Business Week. "In keeping with the Obama administration"s priorities for health-care reform, research directors for several disease areas at J&J said their teams have been doing larger patient studies of experimental drugs that compare them to widely used treatments rather than placebos, a new trend called comparative effectiveness research. And J&J is doing more studies seeking "hard endpoints" -- for example, how many heart attacks or strokes are prevented by a drug, rather than improvements in cholesterol or blood sugar." "Patients and payers increasingly demand such information," BusinessWeek reports, and analysts add that providing it will allow J&J to corner an instant market for the products when new treatments do gain FDA approval (Johnson, 6/4). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009